ArticleThe Journal of experimental medicine1994
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.
Article in The Journal of experimental medicine, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 191 citations in OpenAlex.
- Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing.bioRxiv : the preprint server for biology · 2025Article
- MHC class Ib-restricted CD8Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Roles of CD4+ T cells as mediators of antitumor immunity.Frontiers in immunology · 2022Review
- Short-course neoadjuvant in situ vaccination for murine melanoma.Journal for immunotherapy of cancer · 2022Article
- The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma.Frontiers in oncology · 2020Review
- IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.The Journal of clinical investigation · 2019Article
- A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.Cancer immunology research · 2019Article
- Migratory dendritic cells acquire and present lymphatic endothelial cell-archived antigens during lymph node contraction.Nature communications · 2017Article
- Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.Scientific reports · 2016Article
- Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands.Cancer immunology, immunotherapy : CII · 2016Article
- The dendritic cell cytoskeleton promotes T cell adhesion and activation by constraining ICAM-1 mobility.The Journal of cell biology · 2015Article
- Brain Tumor Immunotherapy: What have We Learned so Far?Frontiers in oncology · 2015Review
- Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.Journal for immunotherapy of cancer · 2015Article
- PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2015Article
- Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase.PloS one · 2014Article
- Molecular profiling of tumor-specific TOncoimmunology · 2013Article
- Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2012Article
- Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Clinical & developmental immunology · 2012Review
- The aging immune system and its relationship with cancer.Aging health · 2011Article
- Combination approaches to potentiate immune response after photodynamic therapy for cancer.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Downregulation of major histocompatibility complex (MHC) class I expression is an important mechanism by which tumors evade classical T cell-dependent immune responses. Therefore, a system was designed to evaluate parameters for active immunization against MHC class I- tumors. Mice were capable of rejecting a MHC class I- tumor challenge after immunization with an irradiated granulocyte/macrophage colony-stimulating factor (GM-CSF) transduced MHC class I- tumor vaccine. This response was critically dependent on CD4+ T cells and natural killer (NK) cells, but minimally on CD8+ T cells. A strong protective response against MHC class I+ variants of the tumor could be elicited when mice were immunized with irradiated MHC class I+ GM-CSF-secreting tumor cells. This response required CD4+ and CD8+ T cells, and in addition, elimination of NK cells resulted in outgrowth of tumors that had lost expression of at least one MHC class I gene. Finally, class I MHC expression on the vaccinating cells inhibited the response generated against a MHC class I- tumor challenge. These results demonstrate that the host is capable of being immunized against a tumor that has lost MHC class I expression and reveal conditions under which distinct effector cells play a role in the systemic antitumor immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.